Iloperidone: A novel atypical antipsychotic for the treatment of schizophrenia

Formulary

Volumn 43, Issue 6, 2008, Pages

  Ehret, Megan J ^a,b   Sopko Jr , Michael A ^a   Levine, Alexander ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b INSTITUTE OF LIVING   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; HALOPERIDOL; ILOPERIDONE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; ZIPRASIDONE;

AKATHISIA; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIZZINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; MAXIMUM PLASMA CONCENTRATION; ORTHOSTATIC HYPOTENSION; PHARMACOGENOMICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; QT INTERVAL; QT PROLONGATION; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT GAIN; XEROSTOMIA;

EID: 46249104302     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
2. Bondy B, Spellmann I. Pharmacogenetics of antipsychotics: Useful for the clinician? Curr Opin Psychiatry. 2007;20:126-130.
3. Reynolds GP, Templeman LA, Godlewska BR. Pharmacogenetics of schizophrenia. Expert Opin Pharmacother. 2006;7:1429-1440.
4. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
5. Hesselink JM. Iloperidone (Novartis). IDrugs. 2002;5:84-90.
6. Albers LJ, Musenga A, Raggi MA. Iloperidone: A new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs. 2008;17:61-75.
7. Vanda presents phase III iloperidone efficacy data [press release]. Rockville, MD: Vanda Pharmaceuticals; December 12, 2007.
8. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904-14.
9. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci. 2000;68:29-39.
10. 1A receptors. Life Sci. 2003;73:1151-1159.
11. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic [erratum in J Clin Pharmacol. 1996;36:92]. J Clin Pharmacol. 1995;35:713-720.
12. Sedek G, Wolfgang C. Iloperidone is well tolerated by subjects with renal or hepatic impairment in single-dose clinical pharmacokinetic studies [abstract]. Presented at: 2007 American Psychiatric Association Annual Meeting; May 19-24, 2007; San Diego, CA. Abstract NR476.
13. Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opin Investig Drugs. 2000;9:2935-2943.
14. Potkin SG, Torres R, Baroldi P, Wolfgang CD. Iloperidone: Placebo- and risperidone-controlled study in patients with schizophrenia [abstract]. Presented at: the 46th Annual Meeting of the American College of Neuropsychopharmacology; December 9-13, 2007; Boca Raton, FL. Abstract 37.
15. Cutler AJ, Kalali AH, Schooler NR, Hamilton J, Polymeropoulos MH, Wolfgang CD. Iloperidone: Placebo- and ziprasidone-controlled study in patients with schizophrenia [abstract]. Presented at: the 46th Annual Meeting of the American College of Neuropsychopharmacology; December 9-13, 2007; Boca Raton, FL. Abstract 20.
16. Licamele L, Volpi S, Heaton C, Mack K, et al. Pharmacogenomic study of iloperidone treatment in patients with schizophrenia identifies markers associated with efficacy [abstract]. Presented at: the 57th Annual Meeting of the American Society of Human Genetics; October 23-27, 2007; San Diego, CA. Abstract 1036/T.
17. Volpi S, Heaton C, Mack K, et al. Pharmacogenomic analysis shows differences in markers associated with response between tow atypical antipsychotics, iloperidone and ziprasidone, in the treatment of patients with schizophrenia [abstract]. Presented at: the 57th Annual Meeting of the American Society of Human Genetics; October 23-27, 2007; San Diego, CA. Abstract 1037/T.
18. Heaton C, Mack K, Volpi S, et al. Whole genome association study identifies polymorphisms in the CERKL gene associated with QT prolongation during iloperidone treatment of patients with schizophrenia [abstract]. Presented at: the 57th Annual Meeting of the American Society of Human Genetics; October 23-27, 2007; San Diego, CA. Abstract 1039/T.
19. c prolongation associated with iloperidone treatment [abstract]. Presented at: the 57th Annual Meeting of the American Society of Human Genetics; October 23-27, 2007; San Diego, CA. Abstract 1040/T.
20. Bardoli P, Wolfgang C. A pharmacokinetic (PK)-pharamcodynamic (PD) relationship exists for efficacy of iloperidone: A novel investigational atypical antipsychotic agent [abstract]. Presented at: 2007 American Psychiatric Association Annual Meeting; May 19-24, 2007; San Diego, CA. Abstract NR507.